Genetic
vulnerability is generally accepted to be involved in the development of
schizophrenia. One of the key genetic factors involved is copy-number
variation, a genetic trait in which people have different numbers of a
particular gene. In particular, variations in the copy number of the ARHGAP10 gene
are associated with symptoms of schizophrenia.
ARHGAP10 encodes
a protein that is involved in the regulation of the Rho GTPase family of
enzymes. Among these Rho GTPase family members, a few reports have implicated
RhoA in schizophrenia. In the current research, the group theorized that some
of the downstream factors of RhoA may be treatment targets. They identified
Rho-associated kinase (ROCK), as a potential therapeutic target, since
activation of the RhoA/ROCK signaling pathway stimulates many risk factors for
schizophrenia.
When model mice
with mutations in their ARHGAP10 gene are bred, they exhibit symptoms similar
to those of human schizophrenia patients. Symptoms include altered spine
density, methamphetamine-induced cognitive dysfunction, and activation of
RhoA/ROCK signaling.
“ROCK signaling
promotes spine shrinkage and destabilization,” said lead researcher Rinako
Tanaka from Nagoya University Graduate School of Medicine. “This is important
because cognitive impairment, such as that seen in schizophrenia, is known to
be associated with spine morphology.”
A team led by the
Nagoya University Graduate School of Medicine, in collaboration with Fujita
Health University, used fasudil to inhibit ROCK in model mice with mutations in
their ARHGAP10 gene to see if this improved symptoms. They found that treatment
restored the density of pyramidal neurons in the medial prefrontal cortex, a
part of the brain associated with attention and long-term memory. As a result,
mice with methamphetamine-induced cognitive impairment treated with the drug
also performed better on visual discrimination tests.
“Our findings
clarify how ROCK contributes to the neuropathological changes in spine
morphology and to the cognitive vulnerability to methamphetamine caused by schizophrenia-associated
mutations in the ARHGAP10 gene,” Tanaka said. “Targeting Rho-kinase
signaling may provide new therapeutic approaches for the treatment of
schizophrenia patients, including those with ARHGAP10 gene mutations.
Inhibitors of Rho kinase, such as fasudil, or those downstream of Rho kinase
may be future therapeutic drugs for schizophrenia.”
Researchers
used the drug fasudil to restore neurons and improve methamphetamine-induced cognitive dysfunction in a mouse model of schizophrenia
(Image credit: Rinako Tanaka, Department of Neuropsychopharmacology Nagoya
University Graduate School of Medicine)
Source: https://www.nagoya-u.ac.jp/researchinfo/result-en/2023/02/20230220-01.html
The paper, “Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene,” has been published in the journal Pharmacological Research at DOI: 10.1016/j.phrs.2022.106589
No comments:
Post a Comment